Lynparza
E505481
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Lynparza canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T5248762 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Lynparza Context triple: [AstraZeneca, notableProduct, Lynparza]
-
A.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
B.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
C.
Keytruda
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
-
D.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
E.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Lynparza Target entity description: Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
A.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
B.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
C.
Keytruda
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
-
D.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
E.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
- F. None of above. chosen
Statements (45)
| Predicate | Object |
|---|---|
| instanceOf |
PARP inhibitor
ⓘ
drug ⓘ small molecule ⓘ targeted cancer therapy ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| associatedWithBiomarker |
BRCA1 mutation
ⓘ
BRCA2 mutation ⓘ |
| coDevelopedBy | Merck & Co. ⓘ |
| developedBy | AstraZeneca ⓘ |
| dosageForm |
capsule
ⓘ
tablet ⓘ |
| firstFDAApprovalYear | 2014 ⓘ |
| hasATCCode | L01XK02 ⓘ |
| hasCommonAdverseEffect |
anemia
ⓘ
diarrhea ⓘ fatigue ⓘ nausea ⓘ vomiting ⓘ |
| hasDrugClass | poly(ADP-ribose) polymerase inhibitor ⓘ |
| hasGenericName | olaparib ⓘ |
| hasIndication |
breast cancer
ⓘ
fallopian tube cancer ⓘ ovarian cancer ⓘ pancreatic cancer ⓘ primary peritoneal cancer ⓘ prostate cancer ⓘ |
| hasIndicationDetail |
maintenance treatment of BRCA-mutated advanced ovarian cancer
ⓘ
maintenance treatment of germline BRCA-mutated metastatic pancreatic adenocarcinoma ⓘ maintenance treatment of recurrent epithelial ovarian cancer ⓘ treatment of germline BRCA-mutated, HER2-negative metastatic breast cancer ⓘ treatment of homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer ⓘ |
| hasPatentStatus | on-patent in many markets as of early 2020s ⓘ |
| hasSeriousAdverseEffect |
acute myeloid leukemia
ⓘ
myelodysplastic syndrome ⓘ pneumonitis ⓘ |
| indicationPopulation | adult patients ⓘ |
| mechanismOfAction |
induces synthetic lethality in tumor cells with BRCA mutations or homologous recombination deficiency
ⓘ
inhibits PARP enzymes involved in DNA repair ⓘ |
| metabolism | CYP3A4 ⓘ |
| pregnancyCategory | can cause fetal harm ⓘ |
| requiresCompanionDiagnostic | BRCA mutation testing for some indications ⓘ |
| routeOfAdministration | oral ⓘ |
| targets |
PARP1
ⓘ
linked to:
PARP enzymes
PARP2 ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Lynparza Description of subject: Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject linked to:
AZN